---
figid: PMC5216829__oncotarget-07-46678-g001
figtitle: Relationship between hypoxia and response to antiangiogenic therapy in metastatic
  colorectal cancer
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC5216829
filename: oncotarget-07-46678-g001.jpg
figlink: /pmc/articles/PMC5216829/figure/F1/
number: F1
caption: 'The mechanisms of action of the three anti-angiogenic drugs (bevacizumab,
  aflibercept and regorafenib) commonly used in mCRC treatment are shown in the lower
  part of the figure. Hypoxia inhibits the activity of PHD enzymes, allowing HIF-1α
  proteins to be stabilized, to dimerize with HIF-1β and to translocate to the nucleus.
  This complex binds hypoxia response elements (HREs) within the promoters of target
  genes. HIF-target genes are involved in cell growth and survival, proliferation,
  metabolic reprogramming, apoptosis and induction of angiogenesis mediated by vascular
  endothelial growth factor and angiopoietins. HIF-1α may also be upregulated in tumor
  cells by the activation of the PI3K-AKT-mTOR pathway. VEGF family members and angiopoietins
  interact with their receptors (VEGFR-1,-2,-3, NP1/2, Tie2), leading to different
  biological consequences. HIF: hypoxia-inducible factor; PHD: prolyl hydroxylase;
  HRE: hypoxia response element; PlGF: placenta growth factor; VEGF: vascular endothelial
  growth factor; VEGFR: vascular endothelial growth factor receptor; NP: neuropilin;
  Ang: angiopoietin.'
papertitle: Relationship between hypoxia and response to antiangiogenic therapy in
  metastatic colorectal cancer.
reftext: Paola Ulivi, et al. Oncotarget. 2016 Jul 19;7(29):46678-46691.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.862089
figid_alias: PMC5216829__F1
figtype: Figure
redirect_from: /figures/PMC5216829__F1
ndex: 5131f53c-df1f-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5216829__oncotarget-07-46678-g001.html
  '@type': Dataset
  description: 'The mechanisms of action of the three anti-angiogenic drugs (bevacizumab,
    aflibercept and regorafenib) commonly used in mCRC treatment are shown in the
    lower part of the figure. Hypoxia inhibits the activity of PHD enzymes, allowing
    HIF-1α proteins to be stabilized, to dimerize with HIF-1β and to translocate to
    the nucleus. This complex binds hypoxia response elements (HREs) within the promoters
    of target genes. HIF-target genes are involved in cell growth and survival, proliferation,
    metabolic reprogramming, apoptosis and induction of angiogenesis mediated by vascular
    endothelial growth factor and angiopoietins. HIF-1α may also be upregulated in
    tumor cells by the activation of the PI3K-AKT-mTOR pathway. VEGF family members
    and angiopoietins interact with their receptors (VEGFR-1,-2,-3, NP1/2, Tie2),
    leading to different biological consequences. HIF: hypoxia-inducible factor; PHD:
    prolyl hydroxylase; HRE: hypoxia response element; PlGF: placenta growth factor;
    VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor
    receptor; NP: neuropilin; Ang: angiopoietin.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Ras85D
  - Pten
  - Akt
  - ph-d
  - Hph
  - tgo
  - sima
  - Mtor
  - Tor
  - es
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - PIG-F
  - 'On'
  - Raf
  - Ret
  - reticulated
  - reti
  - rets
  - btl
  - htl
  - blo
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - PDC
  - ARNT
  - HIF1A
  - MTOR
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - EPAS1
  - HIF3A
  - ARNT2
  - BMAL1
  - PIGF
  - ANGPT1
  - TM7SF2
  - ANGPT2
  - VPS51
  - NPTX1
  - NRP1
  - KDR
  - FLT4
  - FLT1
  - NPTX2
  - NRP2
  - TEK
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - RET
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - PDGFRB
  - PDGFRA
  - KIT
  - Regorafenib
  - Cancer
  - Lung cancer
---
